BioSpace News Archive

Quantabio today announced the commercial availability of the sparQ RNA-Seq HMR Kit , an ultra-fast RNA next-generation sequencing (NGS).

IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE.

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that the Company will present at the Oppenheimer 32nd Annual Healthcare Conference.

Yield10 Bioscience, Inc. today announced that 2021 field test results show that the trait C3020 tested in Camelina and C3007 tested in canola produce increases in seed oil content.

Vericel Corporation today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9th at 1:30 p.m. Eastern Time.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2021 financial results on Tuesday, March 8, 2022, after the market closes.

ValGenesis, Inc., a market leader in enterprise Validation Lifecycle Management Systems (VLMS), and ZeeDimension, a technology and quality consulting company based in Dubai, UAE, have partnered to deliver unique digital validation solutions for pharmaceutical companies in the Middle East.

Screen Therapeutics LLC, today announced preliminary, preclinical findings highlighting the potential of modulating extracellular matrix (ECM) associated proteins.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor under review for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.

Stevanato Group announced that its subsidiary, OMPI of America Inc., entered into an agreement to support the Biomedical Advanced Research and Development Authority pursuant to which BARDA has agreed to provide up to approximately $95 million to Stevanato Group.